V-ATPase blockade reduces renal gluconeogenesis and improves insulin secretion in type 2 diabetic rats

Hypertens Res. 2020 Oct;43(10):1079-1088. doi: 10.1038/s41440-020-0450-0. Epub 2020 May 8.

Abstract

Vacuolar H+-adenosine triphosphatase (V-ATPase) stimulates vesicular acidification that may activate cytoplasmic enzymes, hormone secretion and membrane recycling of transporters. We investigated the effect of blockade of V-ATPase by bafilomycin B1 on renal gluconeogenesis, mitochondrial enzymes, and insulin secretion in type 2 diabetic rats. Spontaneous type 2 diabetic Torii rats were treated with intraperitoneal injection of bafilomycin B1 for 1 week, and the kidneys were examined after 24 h of starvation in metabolic cages. The renal expression and activity of V-ATPase were increased in the brush border membrane of the proximal tubules in diabetic rats. The blockade of V-ATPase by bafilomycin B1 reduced renal V-ATPase activity and urinary ammonium in diabetic rats. Treatment with bafilomycin suppressed the enhanced renal gluconeogenesis enzymes and mitochondrial electron transport enzymes in type 2 diabetic rats and reduced the renal cytoplasmic glucose levels. The insulin index and pancreatic insulin granules were decreased in diabetic rats with increased V-ATPase expression in islet cells, and treatment with bafilomycin B1 reversed these changes and increased the insulin secretion index. Hepatosteatosis in type 2 diabetic rats was ameliorated by bafilomycin treatment. As a consequence, treatment with bafilomycin B1 significantly decreased the plasma glucose level after 24 h of starvation in diabetic rats. In conclusion, a V-ATPase inhibitor improved plasma glucose levels in type 2 diabetes by inhibiting renal mitochondrial gluconeogenesis and improving insulin secretion.

Keywords: Ammoniagenesis; Diabetes; Gluconeogenesis; H+-ATPase; Insulin; Mitochondria.

MeSH terms

  • Animals
  • Blood Glucose / drug effects
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Evaluation, Preclinical
  • Gluconeogenesis / drug effects*
  • Insulin Resistance
  • Insulin Secretion / drug effects*
  • Kidney / drug effects
  • Kidney / enzymology
  • Lipid Metabolism / drug effects
  • Liver / drug effects
  • Macrolides / pharmacology
  • Macrolides / therapeutic use*
  • Male
  • Pancreas / drug effects
  • Rats
  • Vacuolar Proton-Translocating ATPases / antagonists & inhibitors
  • Vacuolar Proton-Translocating ATPases / metabolism

Substances

  • Blood Glucose
  • Macrolides
  • bafilomycin B1
  • Vacuolar Proton-Translocating ATPases